

170.315(h)(1) – Direct Project
Real World Testing 2022**GENERAL INFORMATION**

Plan Report ID Number: 2022v1_H1

Developer Name: Systemedx, Inc.

Product Name(s): Systemedx Clinical Navigator

Version Number(s): 2022.12

Certified Health IT Product List (CHPL) Product Number(s): 15.04.04.2857.Syst.22.01.1.221215

Developer Real World Testing Plan and Result Page URL: <https://www.systemedx.com/mipssolutions.html>

WITHDRAWN PRODUCTS

No certified products were withdrawn in 2023.

170.315(h)(1) – Direct Project Real World Testing 2022

SUMMARY OF TESTING METHODS AND KEY FINDINGS

The data used for reporting this comes from data tracked across 19 clinics.

According to logged data across the participant clinics, the average percentage of confirmed delivered Direct Messages is only 3.8%.

The fourth quarter (October-December) of the year had the most successfully returned response codes at 5.9%. Additionally, specialist settings averaged a higher percentage overall than non-specialty settings with the percentage rising to 4.0% for the year verses 0.49%.

STANDARDS UPDATES (INCLUDING STANDARDS VERSION ADVANCEMENT PROCESS (SVAP) AND UNITED STATES CORE DATA FOR INTEROPERABILITY (USCDI))

Both required and voluntary standards updates must be addressed in the Real World Testing plan. Real World Testing plans must include all certified health IT updated to newer versions of standards prior to August 31 of the year in which the updates were made.

Indicate as to whether optional standards, via SVAP and/or USCDI, are leveraged as part of the certification of your health IT product(s).

☐ Yes, I have products certified with voluntary SVAP or USCDI standards. (If yes, please complete the table below.

☒ No, none of my products include these voluntary standards.

Care Setting(s)

The expectation is that a developer's Real World Testing is conducted within each type of clinical setting in which their certified health IT is marketed. Health IT developers are not required to test their certified health IT in every setting in which it is marketed for use.

List each care setting that was tested.

Ambulatory Internal/Family Medicine
Ambulatory Orthopedics
Ambulatory Allergy Clinics
Other Specialties (including Rheumatology, surgery, neurology)

Metrics and Outcomes

DESCRIPTION OF MEASUREMENT/METRIC

The number of direct messages with receipt confirmations returned vs total messages sent compared across different care settings.

170.315(h)(1) – Direct Project

Real World Testing 2022

ASSOCIATED CERTIFICATION CRITERIA

170.315 (h)(1): Direct Project

OUTCOMES

The expected outcome laid out in the initial plan for this measure is that the percentage of successful transmissions would be above 90% across all care settings.

However, the average percentage of confirmed delivered Direct Messages was only 3.8%. This could be attributed to the fact that vendors have not been required to send response codes back upon reception. The data seems to support this in that most of the messages did not have a matching response code of any kind. So, the assumption is that many vendors in interaction with the test group did not do so.

RELIED UPON SOFTWARE

The information from this measure comes in part from information from third-party relied upon software being interfacing with Surescripts Clinical Direct Messaging service.

KEY MILESTONES

Key Milestone	Care Setting	Date/Timeframe
First Quarter: Observed data over a period of time	Internal Medicine Orthopedics Allergy	Jan - March
Second Quarter: Observed data over a period of time	Internal Medicine Orthopedics Allergy	March - June
Third Quarter: Observed data over a period of time	Internal Medicine Orthopedics Allergy	July - Sept
Fourth Quarter: Observed data over a period of time	Internal Medicine Orthopedics Allergy	Oct - Dec